Source: International Congress 2016 – IPF treatment I
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Paul Noble (Los Angeles, United States of America), Paul Noble, Carlo Albera, Willis Chou, Ulrich Costabel, Bann-mo Day, Ian Glaspole, Marilyn Glassberg, Lisa Lancaster, David Lederer, Steven Nathan, Carlos Pereira, John Stauffer, Jeffrey Swigris. Annual rate of FVC decline in patients with IPF treated with pirfenidone: Pooled analysis from 3 pivotal studies. Eur Respir J 2016; 48: Suppl. 60, 1810

Member's Comments

No comment yet.

Related content which might interest you: Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD) in RECAP Source: International Congress 2016 – IPF treatment I Year: 2016 Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Consistent effect of nintedanib on reducing FVC decline across interstitial lung diseases (ILDs) Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 Short term Quantitative Lung Fibrosis (QLF) change predicts rapid rate of FVC decline in patients with IPF Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 The magnitude of pirfenidone treatment effect in patients with idiopathic pulmonary fibrosis (IPF): A pooled analysis of outcomes in the CAPACITY (CAP) studies Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Effect of baseline FVC on decline in lung function with nintedanib: Results from the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Real World experiences: Pirfenidone is well tolerated and reduces decline in FVC and TLCO at 9 months in IPF Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Effect of pirfenidone on treatment-emergent (TE) all-cause mortality (ACM) in patients with idiopathic pulmonary fibrosis (IPF): Pooled data analysis from ASCEND and CAPACITY Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS trial Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Association between weight loss and decline in FVC in patients with IPF Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 Lung function decline in COPD trials Source: Eur Respir J 2009; 33: 708-709 Year: 2009 FVC decline over 1 year predicts mortality but not subsequent FVC decline in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017